| pMSCV-LTR-dCas9-VP64-BFP | dCas9-VP64-BFP fusion (Homo sapiens), Puromycin resistance | LTR, PGK | Puromycin |
Qi
| CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes.
Cell. 2013 Jul 9. pii: S0092-8674(13)00826-X. doi: 10.1016/j.cell.2013.06.044.
|
Human expression vector containing MSCV LTR promoter, dCas9 that is fused to 2x NLS, VP64 and tagBFP
MSCV-puro
|
| pMSCV-LTR-dCas9-p65AD-BFP | dCas9-p65AD-BFP fusion (Homo sapiens), Puromycin resistance | LTR, PGK | Puromycin |
Qi
| CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes.
Cell. 2013 Jul 9. pii: S0092-8674(13)00826-X. doi: 10.1016/j.cell.2013.06.044.
|
Human expression vector containing MSCV LTR promoter, dCas9 that is fused to 2x NLS, p65 activation domain and tagBFP
MSCV-puro
|
| pcDNA-dCas9-VP64 | dCas9-VP64 (Other) | CMV | |
Gersbach
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors.
Nat Methods. 2013 Jul 25. doi: 10.1038/nmeth.2600.
|
Expresses inactivated S. pyogenes dCas9 (D10A, H840A) fused to VP64 transactivator domain in mammalian cells
pcDNA3.1
|
| Cas9m2-VP64 | Cas9m2-VP64 (Other) | | |
Church
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol. 2013 Aug 1. doi: 10.1038/nbt.2675.
|
Cas9m2 Activator
pcDNA3.3_TOPO
|
| Cas9m3-VP64 | Cas9m3-VP64 (Other) | | |
Church
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol. 2013 Aug 1. doi: 10.1038/nbt.2675.
|
Cas9m3 Activator
pcDNA3.3_TOPO
|
| Cas9m4-VP64 | Cas9m4-VP64 (Other) | | |
Church
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering.
Nat Biotechnol. 2013 Aug 1. doi: 10.1038/nbt.2675.
|
Cas9m4 Activator
pcDNA3.3_TOPO
|
| pSL690 | dCas9-VP64 (Synthetic) | CMV | |
Joung
| CRISPR RNA-guided activation of endogenous human genes.
Nat Methods. 2013 Jul 25. doi: 10.1038/nmeth.2598.
|
Expresses dCas9-VP64 fusion
unknown
|
| pMLM3705 | codon optimized dCas9-VP64 (Synthetic) | CMV | |
Joung
| CRISPR RNA-guided activation of endogenous human genes.
Nat Methods. 2013 Jul 25. doi: 10.1038/nmeth.2598.
|
Expresses mammalian cell codon-optimized dCas9-VP64
pJDS246
|
| pAC1-pCR8-dCas9VP48 | dCas9(D10A;H840A) fusion with VP48 activation domain (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP48 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC147-pCR8-dCas9VP64 | dCas9(D10A;H840A) fusion with VP64 activation domain (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP64 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC148-pCR8-dCas9VP96 | dCas9(D10A;H840A) fusion with VP96 activation domain (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP96 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC149-pCR8-dCas9VP160 | dCas9(D10A;H840A) fusion with VP160 activation domain (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160 on Gateway donor vector pCR8/GW/TOPO. Note: This is not for expression. It has to be transferred to a gateway destination vector for expression
pCR8/GW/TOPO
|
| pAC91-pmax-dCas9VP64 | dCas9(D10A;H840A) fusion with VP64 activation domain (Homo sapiens) | CAGGS | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP64 on pmax expression vector
pmax-DEST (Addgene: 48222)
|
| pAC92-pmax-dCas9VP96 | dCas9(D10A;H840A) fusion with VP96 activation domain (Homo sapiens) | CAGGS | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP96 on pmax expression vector
pmax-DEST (Addgene: 48222)
|
| pAC93-pmax-dCas9VP160 | dCas9(D10A;H840A) fusion with VP160 activation domain (Homo sapiens) | CAGGS | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160 on pmax expression vector
pmax-DEST (Addgene: 48222)
|
| pAC94-pmax-dCas9VP160-2A-puro | dCas9(D10A;H840A) fusion with VP160 activation domain followed by 2A-puro (Homo sapiens) | CAGGS | Puromycin |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160-2A-puro (puro-selectable) on pmax expression vecor. Note: This is being tested.
pmax-DEST (Addgene: 48222)
|
| pAC95-pmax-dCas9VP160-2A-neo | dCas9(D10A;H840A) fusion with VP160 activation domain followed by 2A-neo (Homo sapiens) | CAGGS | Neomycin (select with G418) |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
dCas9VP160-2A-neo (neo/G418-selectable) on pmax expression vector. Note: This is being tested.
pmax-DEST (Addgene: 48222)
|
| pAC2-dual-dCas9VP48-sgExpression | dCas9VP48 (Homo sapiens) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP48 and sgRNA from separate promoters
pX335 (Addgene #42335)
|
| pAC5-dual-dCas9VP48-sgTetO | dCas9VP48 and sgTetO (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP48 and sgTetO from separate promoters
pAC2-dual-dCas9VP48-sgExpression (Addgene #48236)
|
| pAC152-dual-dCas9VP64-sgExpression | dCas9 (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP64 and sgRNA from separate promoters
pX335 (Addgene #42335)
Tags
/ Fusion Proteins- HA-Tag (N terminal on insert)
- VP64 (C terminal on insert)
|
| pAC153-dual-dCas9VP96-sgExpression | dCas9 (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP96 and sgRNA from separate promoters
pX335 (Addgene #42335)
Tags
/ Fusion Proteins- HA-Tag (N terminal on insert)
- VP96 (C terminal on insert)
|
| pAC154-dual-dCas9VP160-sgExpression | dCas9 (Synthetic) | | |
Jaenisch
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system.
Cell Res. 2013 Aug 27. doi: 10.1038/cr.2013.122.
|
Dual expression construct expressing both dCas9VP160 and sgRNA from separate promoters
pX335 (Addgene #42335)
Tags
/ Fusion Proteins- HA-Tag (N terminal on insert)
- VP160 (C terminal on insert)
|
| M-SPn-VP64 | Cas9-VP64, nuclease-null (Other) | CMV | Neomycin (select with G418) |
Church
| Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.
Nat Methods. 2013 Sep 29. doi: 10.1038/nmeth.2681.
|
Mammalian SP-VP64 nuclease-null Cas9 activator expression, human optimized
pcDNA3.3 TOPO
|
| M-ST1n-VP64 | Cas9-VP64, nuclease-null (Other) | CMV | Neomycin (select with G418) |
Church
| Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.
Nat Methods. 2013 Sep 29. doi: 10.1038/nmeth.2681.
|
Mammalian ST1-VP64 nuclease-null Cas9 activator expression, human optimized
pcDNA3.3 TOPO
|
| M-NMn-VP64 | Cas9-VP64, nuclease-null (Other) | CMV | Neomycin (select with G418) |
Church
| Orthogonal Cas9 proteins for RNA-guided gene regulation and editing.
Nat Methods. 2013 Sep 29. doi: 10.1038/nmeth.2681.
|
Mammalian NM-VP64 nuclease-null Cas9 activator expression, human optimized
pcDNA3.3 TOPO
|
| pCMV_dCas9_VP64 | dCas9_VP64 (human-codon-optimized) (Homo sapiens) | CMV | |
Lu
| Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR/Cas.
ACS Synth Biol. 2013 Sep 11.
|
encodes human-optimized dCas9_VP64 synthetic transcription factor
phi-Yellow-Dest
|
| pHAGE TRE dCas9-VP64 | dCas9 (Other) | TRE | Neomycin (select with G418) |
Wolfe
| Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells.
Development. 2014 Jan;141(1):219-23. doi: 10.1242/dev.103341.
|
Tet-regulatable dCas9-VP64 lentiviral expression vector
pHAGE
|
| pHAGE EF1α dCas9-VP64 | dCas9 (Other) | EF1alpha | Puromycin |
Wolfe
| Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells.
Development. 2014 Jan;141(1):219-23. doi: 10.1242/dev.103341.
|
Constitutive dCas9-VP64 lentiviral expression vector
pHAGE
|
| pLV hUbC-dCas9 VP64-T2A-GFP | humanized dead Cas9 VP64 T2A GFP (Other) | hUbC | |
Gersbach
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
Nucleic Acids Res. 2014 Aug 13. pii: gku749.
|
Co-expresses human optimized S. pyogenes dCas9-VP64 and GFP
FUGW
|
| CMVp-dCas9-3xNLS-VP64 (Construct 1) | dCas9 (Homo sapiens) | CMV/hUBC | |
Lu
| Multiplexed and Programmable Regulation of Gene Networks with an Integrated RNA and CRISPR/Cas Toolkit in Human Cells.
Mol Cell. 2014 May 14. pii: S1097-2765(14)00355-4. doi: 10.1016/j.molcel.2014.04.022.
|
Expresses taCas9 in Mammalian cells for transactivating endogenous and synthetic promoters. The backbone is a lentiviral vector.
pFUGw (Addgene id: 25870)
|
| pLV hUbC-VP64 dCas9 VP64-T2A-GFP | humanized VP64 dead Cas9 VP64 T2A GFP (Other) | | |
Gersbach
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector.
Nucleic Acids Res. 2014 Aug 13. pii: gku749.
|
Co-expresses human optimized S. pyogenes dCas9 fused to two copies of VP64 and GFP
FUGW
|
| pcDNA3.1-CibN-dCas9 | CibN-dCas9 (Arabidopsis thaliana) | CMV | Neomycin (select with G418) |
Gersbach
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Nat Chem Biol. 2015 Feb 9. doi: 10.1038/nchembio.1753.
|
Expresses CibN-dCas9 in mammalian cells
pcDNA3.1
|
| pcDNA3.1-dCas9-CibN | dCas9-CibN (Arabidopsis thaliana) | CMV | Neomycin (select with G418) |
Gersbach
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Nat Chem Biol. 2015 Feb 9. doi: 10.1038/nchembio.1753.
|
Expresses dCas9-CibN in mammalian cells
pcDNA3.1
|
| pcDNA3.1-CibN-dCas9-CibN | dCas9-CibN (Arabidopsis thaliana) | CMV | Neomycin (select with G418) |
Gersbach
| A light-inducible CRISPR-Cas9 system for control of endogenous gene activation.
Nat Chem Biol. 2015 Feb 9. doi: 10.1038/nchembio.1753.
|
Expresses CibN-dCas9-CibN in mammalian cells
pcDNA3.1
|
| pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP | Cas9 dead | | |
Vale
| A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging.
Cell. 2014 Oct 8. pii: S0092-8674(14)01227-6. doi: 10.1016/j.cell.2014.09.039.
|
Expressed a nuclease dead Cas9 tagged with 10 copies of the GCN4 peptide v4 and BFP. This plasmid is part of the SunTag system for gene activation
pHR
|
| pHRdSV40-scFv-GCN4-sfGFP-VP64-GB1-NLS | scFv-GCN4 | | |
Vale
| A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging.
Cell. 2014 Oct 8. pii: S0092-8674(14)01227-6. doi: 10.1016/j.cell.2014.09.039.
|
The plasmid encodes a antibody that binds to the GCN4 peptide from the SunTag system, and is fused to a transcriptional activation domain VP64
pHR
|
| pHRdSV40-NLS-dCas9-24xGCN4_v4-NLS-P2A-BFP-dWPRE | dCas9 | dSV40 Promoter | |
Vale
| A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging.
Cell. 2014 Oct 8. pii: S0092-8674(14)01227-6. doi: 10.1016/j.cell.2014.09.039.
|
dCas9 fused to 24 copies of the GCN4 peptide v4, which is part of the SunTag system
pHR
|
| pcDNA-dCas9-FLp300 | S.pyogenes dCas9 with c-terminal full length human p300 (aa 2-2414) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of FL human p300 (aa 2-2414) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (D1399Y) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inactivating mutation D1399Y) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (1645/1646 RR/EE) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; mutation 1645/1646 RR/EE) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (C1204R) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; mutation C1204R) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (Y1467F) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inavtivating mutation Y1467F) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (1396/1397 SY/WW) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inactivating mutation 1396/1397 SY/WW) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA-dCas9-p300 Core (H1415A/E1423A/Y1424A/L1428S/Y1430A/H1434A) | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens) | CMV | |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes S. pyogenes dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664; inactivating mutations H1415A/E1423A/Y1424A/L1428S/Y1430A/H1434A) driven by CMV promoter
pcDNA3.1
EP300 KAT3B, RSTS2, p300
|
| pcDNA3.3-Nm-dCas9-p300 Core | Nm-dCas9-p300 Core (Homo sapiens) | CMV | Neomycin (select with G418) |
Gersbach
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Nat Biotechnol. 2015 May;33(5):510-7. doi: 10.1038/nbt.3199. Epub 2015 Apr 6.
|
encodes N. meningiditis dCas9 with c-terminal fusion of human p300 HAT core (aa 1048-1664) driven by CMV promoter
pcDNA3.3
EP300 KAT3B, RSTS2, p300
|
| dCAS9-VP64_GFP | dCAS9(D10A,H840A)-VP64_2A_GFP (Synthetic) | EF1A | GFP |
Zhang
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
Nature. 2014 Dec 10. doi: 10.1038/nature14136.
|
Expresses dCAS9-VP64 activator with 2A GFP
lenti(AMP)
|
| lenti dCAS-VP64_Blast | dCAS9(D10A, N863A)-VP64_2A_Blast (Synthetic) | EF1A | Blasticidin |
Zhang
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.
Nature. 2014 Dec 10. doi: 10.1038/nature14136.
|
3rd generation lenti vector encoding dCAS9-VP64 with 2A Blast resistance marker (EF1a-NLS-dCas9(N863)-VP64-2A-Blast-WPRE)
plenti
|
| TetO-FUW-VdC9BV | VP64dCas9BFPVP64 (Synthetic) | | |
Leong
| A CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification.
Stem Cell Reports. 2014 Dec 9;3(6):940-7. doi: 10.1016/j.stemcr.2014.09.013. Epub 2014 Oct 23.
|
Expresses RNA-Guided, Nuclease-Inactive VP64:dCas9-BFP:VP64—VdC9BV—Fusion Protein to Enable Transactivation of Endogenous Genes
TetO-FUW
|
| pJZC32 | sgRNA, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA (no RNA aptamer addition) with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC25 | sgRNA + 1x MS2 binding module, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1x MS2 with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC33 | sgRNA + 2x MS2 binding module, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2x MS2 with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC34 | sgRNA + 2x MS2(wt+f6) binding module, MCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2x MS2(wt+f6) with MCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC41 | sgRNA, PCP-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA (no RNA aptamer addition) with PCP-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC39 | sgRNA + 1x PP7, mCherry | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1x PP7 with mCherry for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC101 | sgRNA, COM-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA (no RNA aptamer addition) with COM-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC48 | sgRNA + 1x COM binding module, COM-VP64 | U6, CMV | Marked by mCherry |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1x COM with COM-VP64 effector for mammalian cells
MP177_U6 (derived from pSico)
|
| pJZC116 | sgRNA + 2x MS2 (wt+f6) binding module, MCP-VP64 | U6, CMV | Marked by BFP |
Qi
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2x MS2(wt+f6) with MCP-VP64 effector for mammalian cells, marked by BFP
MP177_U6 (derived from pSico)
|
| PX855 | SpCas9 (aa 2-535) | CBh | |
Zhang
| A split-Cas9 architecture for inducible genome editing and transcription modulation.
Nat Biotechnol. 2015 Feb 2. doi: 10.1038/nbt.3149.
|
N-term SpCas9 piece of inducible transcriptional activator (dCas9(N)-FRB-2xNES)
PX330
|
| PX856 | SpCas9 (aa536-1368) | CBh | |
Zhang
| A split-Cas9 architecture for inducible genome editing and transcription modulation.
Nat Biotechnol. 2015 Feb 2. doi: 10.1038/nbt.3149.
|
C-term SpCas9 piece of inducible transcriptional activator (dCas9(C)-FKBP-2xNLS-VP64)
PX330
|
| SP-dCas9-VPR | SP-dCas9-VPR (Homo sapiens) | CMV | Neomycin (select with G418) |
Church
| Highly efficient Cas9-mediated transcriptional programming.
Nat Methods. 2015 Mar 2. doi: 10.1038/nmeth.3312.
|
SP-dCas9 with VP64-p65-Rta (VPR) fused to it's C-terminus; mammalian vector
pcDNA3.3 TOPO
|
| M_ST1n_VPR | ST1-dCas9-VPR (Homo sapiens) | CMV | Neomycin (select with G418) |
Church
| Highly efficient Cas9-mediated transcriptional programming.
Nat Methods. 2015 Mar 2. doi: 10.1038/nmeth.3312.
|
ST1-dCas9 with VP64-p65-Rta (VPR) fused to it's C-terminus; mammalian vector
pcDNA3.3 TOPO
|
| PB-TRE-dCas9-VPR | dCas9-VPR (Homo sapiens) | TRE | Hygromycin |
Church
| Highly efficient Cas9-mediated transcriptional programming.
Nat Methods. 2015 Mar 2. doi: 10.1038/nmeth.3312.
|
SP-dCas9-VPR with doxycycline-inducible expression
PB-TRE
|
| NLS-dCas9-trCIB1 | dCas9-trCIB1 fusion (Synthetic) | CMV | Neomycin (select with G418) |
Sato
| CRISPR-Cas9-based Photoactivatable Transcription System.
Chem Biol. 2015 Feb 19;22(2):169-74. doi: 10.1016/j.chembiol.2014.12.011. Epub 2015 Jan 22.
|
Photoactivatable transcription system. Expression of genomic anchor probe, containing
dCas9 and CIB1
pcDNA3.1/V5-His A
|
| pJZC42 | sgRNA + 1XPP7, PCP-VP64 IRES mCherry | U6, CMV | mCherry fluorescence |
Lim
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 1XPP7 with PCP-VP64 effector for mammalian cells, marked by mCherry
pSico
|
| pJZC43 | sgRNA + 2XPP7, PCP-VP64 IRES mCherry | U6, CMV | mCherry fluorescence |
Lim
| Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds.
Cell. 2014 Dec 18. pii: S0092-8674(14)01570-0. doi: 10.1016/j.cell.2014.11.052.
|
sgRNA + 2XPP7 with PCP-VP64 effector for mammalian cells, marked by mCherry
pSico
|
| pEF_dCas9-VP64 | dCas9 (Other) | human EF1[alpha] | |
Rinn
| Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display.
Nat Methods. 2015 Jul;12(7):664-70. doi: 10.1038/nmeth.3433. Epub 2015 Jun 1.
|
Transient expression of Sp-dCas9 fused to the VP64 transcription activator, in mammalian cells, under an EF1-alpha promoter.
pNEB193
Tags
/ Fusion Proteins- 3xFLAG (C terminal on insert)
- VP64 (C terminal on insert)
|
| AAV_NLS-dSaCas9-NLS-VPR | dSaCas9-VPR (Synthetic) | CMV | |
Church
| Cas9 gRNA engineering for genome editing, activation and repression.
Nat Methods. 2015 Sep 7. doi: 10.1038/nmeth.3580.
|
AAV vector containing nuclease null SaCas9 fused to VPR
pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA Plasmid #61592
|
| CAG-DDdCas9VP192-T2A-EGFP-ires-puro | DD-dCas9VP192-T2A-EGFP (Other) | CAG | Puromycin |
Otonkoski
| Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.
|
DHFR destabilised domain (DD) fused to dCas9VP192 (S.pyogenes) on CAG expression vector. DDdCas9VP192 protein is stabilised by Trimethoprim.
PyCAG
|
| pCXLE-dCas9VP192-T2A-EGFP-shP53 | dCas9-dCas9VP192-GFP-shp53 (Other) | CAG | |
Otonkoski
| Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.
|
Episomal plasmid encoding dCas9VP192 and p53 shRNA
pCXLE
|
| pCXLE-dCas9VP192-T2A-EGFP | dCas9-dCas9VP192-EGFP (Other) | CAG | |
Otonkoski
| Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation.
Stem Cell Reports. 2015 Sep 8;5(3):448-59. doi: 10.1016/j.stemcr.2015.08.001.
|
Episomal plasmid encoding dCas9VP192
pCXLE
|
| pHRm-NLS-dCas9-GFP11x7-NLS-P2A-BFP-NLS | NLS-dCas9-GFP11x7-NLS-P2A-BFP-NLS (Synthetic) | | |
Huang
| Versatile protein tagging in cells with split fluorescent protein.
Nat Commun. 2016 Mar 18;7:11046. doi: 10.1038/ncomms11046.
|
Expresses NLS-dCas9-GFP11x7-NLS and BFP-NLS in mammalian cells
pHRdSV40-NLS-dCas9-24xGCN4_v4-NLS-P2A-BFP-dWPRE (addgene #60910)
|
| pAC164-pmax-dCas9Master-VP64 | dCas9-VP64 (Synthetic) | CAGGS + chim intron | |
Cheng
| Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.
Cell Res. 2016 Feb;26(2):254-7. doi: 10.1038/cr.2016.3. Epub 2016 Jan 15.
|
dCas9-3xGGGGS-VP64 in pmax expression vector
pAC90-pmax-DEST
|
| pAC1364-pmax-dCas9Master_mCBPHAT | dCas9-mCBPHAT (Synthetic) | CAGGS + chim intron | |
Cheng
| Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.
Cell Res. 2016 Feb;26(2):254-7. doi: 10.1038/cr.2016.3. Epub 2016 Jan 15.
|
dCas9Master_mCBPHAT in pmax expression vector
pAC90-pmax-DEST
|
| pAC1410-pmax-dCas9Master_p65HSF1 | dCas9-p65HSF1 (Synthetic) | CAGGS + chim intron | |
Cheng
| Casilio: a versatile CRISPR-Cas9-Pumilio hybrid for gene regulation and genomic labeling.
Cell Res. 2016 Feb;26(2):254-7. doi: 10.1038/cr.2016.3. Epub 2016 Jan 15.
|
dCas9Master_p65HSF1 in pmax expression vector
pAC90-pmax-DEST
|
| lentiSAMv2 | | U6 and EF1A | Blasticidin |
Zhang
| Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening.
Nat Protoc. 2017 Apr;12(4):828-863. doi: 10.1038/nprot.2017.016. Epub 2017 Mar 23.
|
lenti sgRNA cloning backbone with MS2 loops at tetraloop and stemloop 2, dCas9-VP64, and blast resistance marker. Contains BsmBI sites for insertion of spacer sequences.
plenti
|
| pLV-dCas9-p300-P2A-PuroR | S.pyogenes dCas9 with c-terminal human p300 Core effector fusion (aa 1048-1664 of human p300) (Homo sapiens), pac from Streptomyces alboniger (Other) | EFS | Puromycin |
Gersbach
| CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
Nat Biotechnol. 2017 Apr 3. doi: 10.1038/nbt.3853.
|
Lentiviral Sp dCas9-p300-P2A-PuroR
lentiCRISPR v2
EP300 KAT3B, RSTS2, p300
|
| AAVS1-idCas9-vpr | dCas9-VPR (Other) | TRE-tight | Puromycin |
Na
| An inducible CRISPR-ON system for controllable gene activation in human pluripotent stem cells.
Protein Cell. 2017 Jan 23. doi: 10.1007/s13238-016-0360-8.
|
inducible CRISPR-ON system for controllable gene activation; this plasmid is used to insert dCas9-VPR casette in one allele of AAVS1 locus
AAVS1 homologous recombineering donor plasmid
|
| lentiSAM v2 (Puro) | | U6 (sgRNA) and EF1a (dCas9-VP64) | Puromycin |
Karpf
|
Lenti CRISPR Activate
(unpublished)
|
Modified version of lentiSAM v2, a lenti sgRNA cloning backbone with MS2 loops at tetraloop/stemloop 2, dCas9-VP64, and puro resistance marker. Contains BsmBI sites for insertion of spacer sequences.
lentiSAM v2
|
| pXPR_120 | dCas9 (Other) | EF1a | Blasticidin |
Root
|
Najm et al.
(unpublished)
|
for CRISPRa, lentiviral expression of dCas9-VPR 2A BlastR
pXPR
Tag
/ Fusion Protein- VPR (C terminal on insert)
|
| lenti-EF1a-dCas9-VP64-Puro | dCas9-VP64-T2A-Puro (Synthetic) | EF-1a | Puromycin, Zeocin |
Brennand
| Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.
Stem Cell Reports. 2017 Aug 8;9(2):615-628. doi: 10.1016/j.stemcr.2017.06.012. Epub 2017 Jul 27.
|
3rd generation lenti vector encoding dCas9-VP64 with 2A puromycin resistance marker (EF1a-dCas9-VP64-T2A-Puro-WPRE)
pLenti
|
| lenti-EF1a-dCas9-VPR-Puro | (Sp)dCas9-VPR-P2A-Puro (Homo sapiens) | EF-1a | Puromycin, Zeocin |
Brennand
| Evaluating Synthetic Activation and Repression of Neuropsychiatric-Related Genes in hiPSC-Derived NPCs, Neurons, and Astrocytes.
Stem Cell Reports. 2017 Aug 8;9(2):615-628. doi: 10.1016/j.stemcr.2017.06.012. Epub 2017 Jul 27.
|
3rd generation lenti vector encoding dCas9 (S. pyogenes) fused with VP64-p65-Rta (VPR) and 2A puromycin resistance marker; EF1a-dCas9-VPR-P2A-Puro-WPRE)
pLenti
|
| PB-UniSAM | UniSAM-mCherry + U6-gRNA2.0 | EF1a | mCherry |
Forrester
| An all-in-one UniSam vector system for efficient gene activation
Scientific Reports
|
Encodes for Cas9-VP64, MS2-p65-HSF1, mCherry and for the gRNA 2.0
Piggy Bac
|
| pTMt_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | TMt-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to transmembrane tether
pX856
|
| pVEGFR1_TEV(C)_TCS(Q'G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | VEGFR1-dCas9(C) | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to VEGFR1
pTMt_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | BDKRB2-dCas9(N) | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to BDKRB2
pTMt_TCS(Q’G)_NLSHA- dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)_T2A_DHFR-PCP-VP64 | BDKRB2-dCas9(C)_DHFR-PCP-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C) with DHFR-PP7-VP64 fused to BDKRB2
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pAVPR2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | AVPR2-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to AVPR2
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pCXCR4_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | CXCR4-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to CXCR4
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| pLPAR1_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1 | LPAR1-dCas9(C)-VP64 | | |
Fulga
| Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.
Cell Rep. 2017 Sep 12;20(11):2639-2653. doi: 10.1016/j.celrep.2017.08.044.
|
Encodes dCas9(C)-VP64 with SAM components fused to LPAR1
pBDKRB2_TCS(Q’G)_NLS-HA-dCas9(C)-VP64_T2A_MCP-P65-HSF1
|
| IGI-P0492 pHR-dCas9-NLS-VPR-mCherry | dCas9-VPR-mCherry (Homo sapiens) | CAG | mCherry |
Corn
|
Corn Lab Cas9 plasmids
(unpublished)
|
Lentiviral expression of dCas9-VPR-mCherry fusion protein for CRISPRa.
pHR
Tag
/ Fusion Protein- NLS-VPR-mCherry (C terminal on insert)
|
| PB-SAM | MS2-P65-HSF1_T2A_Hygro (Homo sapiens), dCAS9(D10A, N863A)-VP64_T2A_Blast (Synthetic) | EF1A, CAG | Hygromycin, Blasticidin |
Liu
| One-Step piggyBac Transposon-Based CRISPR/Cas9 Activation of Multiple Genes.
Mol Ther Nucleic Acids. 2017 Sep 15;8:64-76. doi: 10.1016/j.omtn.2017.06.007. Epub 2017 Jun 15.
|
Piggybac transposon vector encoding dCAS9-VP64 and MS2-P65-HSF1 activator helper complex.
piggybac
|
| PB-SAM-Dest | | N/A | Hygromycin, Blasticidin |
Liu
| One-Step piggyBac Transposon-Based CRISPR/Cas9 Activation of Multiple Genes.
Mol Ther Nucleic Acids. 2017 Sep 15;8:64-76. doi: 10.1016/j.omtn.2017.06.007. Epub 2017 Jun 15.
|
Piggybac transposon DEST vector encoding dCAS9-VP64 and MS2-P65-HSF1 activator helper complex. It is used for insertion of multiple U6-sgRNA expression cassettes.
PB-SAM
|
| pAW90.dCas9-YY1 | dCas9-YY1 | | Blasticidin |
Young
| YY1 Is a Structural Regulator of Enhancer-Promoter Loops.
Cell. 2017 Dec 14;171(7):1573-1588.e28. doi: 10.1016/j.cell.2017.11.008. Epub 2017 Dec 7.
|
Expresses dCas9-YY1
dcas9-vp64
|
| JG1202: CAG-human dLbCpf1(D832A)-NLS-3xHA-P65 | dLbCpf1(D832A)-p65 (Other) | CAG | |
Joung
| Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors.
Nat Methods. 2017 Oct 30. doi: 10.1038/nmeth.4483.
|
Mammalian expression vector for catalytically inactive Cpf1 from Lachnospiraceae bacterium (dLbCpf1) fused to p65 activation domain
pCAG-GFP
|
| dxCas(3.7)-VPR | dxCas(3.7)-VPR (Synthetic) | | |
Liu
| Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
Nature. 2018 Feb 28. pii: nature26155. doi: 10.1038/nature26155.
|
Mammalian expression vector for xCas9 3.7 with VP64-p65-Rta (VPR) fused to its C-terminus
pCMV
Tag
/ Fusion Protein- NLS (N terminal on insert)
|
| dxCas(3.6)-VPR | dxCas(3.6)-VPR (Synthetic) | | |
Liu
| Evolved Cas9 variants with broad PAM compatibility and high DNA specificity.
Nature. 2018 Feb 28. pii: nature26155. doi: 10.1038/nature26155.
|
Mammalian expression vector for xCas9 3.6 with VP64-p65-Rta (VPR) fused to its C-terminus
pCMV
Tag
/ Fusion Protein- NLS (N terminal on insert)
|